ClinConnect ClinConnect Logo
Search / Trial NCT06991153

Impact of Lung Boost Device on Ventilatory Functions and Fatigue in Patients With Interstitial Lung Diseases

Launched by CAIRO UNIVERSITY · May 22, 2025

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring how a special exercise device, called the lung boost device, can help improve breathing, reduce fatigue, and enhance physical ability in women with interstitial lung disease (ILD). The study aims to understand if using this device can make a positive difference in the daily lives of patients who have been living with ILD for at least three years and experience mild breathing difficulties.

To participate in this trial, women aged 45 to 55 with a confirmed diagnosis of ILD and stable health conditions may be eligible. However, those with certain heart issues, other serious lung diseases, cognitive problems, or recent treatments for cancer or infections will not be included. Participants can expect to engage in exercises using the lung boost device and will be monitored to see how it affects their breathing and overall well-being. This research could help find new ways to support patients with ILD.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Forty female patients have Interstitial lung disease .
  • 2. All patients diagnosed as ILD on clinical and radiological basis.
  • 3. Age will range between 45 to 55 years old .
  • 4. All patients will be with mild hypoxemia range from 90 to 92 oxygen saturation
  • 5. They have Interstitial lung disease for at least 3 years ago.
  • 6. Stable in medical and hemodynamic state
  • Exclusion Criteria:
  • 1. Cardiovascular (as acute heart failure, unstable angina or recent myocardial infarction)
  • 2. Patients with other significant respiratory disorders such as acute infections, pulmonary tuberculosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, lung carcinoma, and pneumothorax.
  • 3. cognitive impairments, history of cerebrovascular accident, active cancer will be excluded.
  • 4. Hepatitis, cirrhosis.
  • 5. Current treatment for cancer or active infection
  • 6. Orthopedic problem.

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Giza, , Egypt

Patients applied

0 patients applied

Trial Officials

Nesreen Gharib El Nahas, PhD

Study Chair

Professor, Cairo university

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported